Document is current

Article History

Accepted: 18 March 2022

First Online: 4 November 2022

Declarations

:

: M. Holtkamp has received honoraria for consulting and lectures from Angelini/Arvelle, Bial, Desitin, Eisai, GW Pharma, UCB, and Zogenix from 2018 to 2022. He is coordinator of the guideline group “Management of First Epileptic Seizure and Epilepsies” of the German Neurological Society. He is also an associate member of the Drug Commission of the German Medical Association and advises the Federal Joint Committee on issues related to the pharmacological treatment of epileptic seizures and epilepsy. G. Krämer has received honoraria for consulting and lectures from Arvelle Therapeutics, GW Pharmaceuticals/Jazz Pharma, OM Pharma Suisse, Precisis, and Sandoz from 2018 to 2022. He is or has been a member of the German Neurological Society’s guideline group on “Management of First Epileptic Seizure and Epilepsies” and the ILAE Task Force on Epilepsy in the Elderly (2017–2021).

: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.

: The supplement containing this article is not sponsored by industry.

Free to read: This content has been made available to all.